NMN

Nicotinamide mononucleotide

Grade B: Human evidence, not approved for this use

TL;DR: NMN (nicotinamide mononucleotide) is an NAD+ precursor with a genuine human RCT evidence base, though the trials are small, short-duration, and largely focused on surrogate endpoints rather than clinical disease outcomes. Published RCTs have found that oral NMN raises blood NAD+ levels, and several trials in healthy middle-aged adults, older men, and women with prediabetes have reported improvements in markers such as muscle oxygen utilization, aerobic capacity in runners, and insulin sensitivity. A multicenter double-blind placebo-controlled trial found dose-dependent changes in NAD+ levels but limited functional outcomes. No trial has demonstrated effects on human aging, longevity, or disease incidence. Long-term safety data beyond 12 weeks is sparse. NMN's regulatory status in the US has been clarified: the FDA reversed a prior drug-exclusion determination in September 2025 and confirmed NMN is lawful as a dietary supplement, though New Dietary Ingredient notification requirements apply.

Key Takeaways

Grade B: Human evidence, not approved for this use
Not FDA approved: Not an FDA-approved drug; confirmed lawful as a dietary supplement in the US as of September 2025, subject to NDI notification requirements.
Compounding: NMN is not a compounded drug; it is legally sold as a dietary supplement in the US as of September 2025 (FDA reversed its prior drug-exclusion position). New Dietary Ingredient notification is required from manufacturers. It is not an FDA-approved drug for any indication.

Mechanism

Serves as a direct precursor to NAD+ (nicotinamide adenine dinucleotide) via the salvage pathway, raising intracellular NAD+ levels that decline with age and that support mitochondrial energy metabolism and sirtuin-mediated cellular repair pathways.

Evidence

NMN (nicotinamide mononucleotide) is an NAD+ precursor with a genuine human RCT evidence base, though the trials are small, short-duration, and largely focused on surrogate endpoints rather than clinical disease outcomes. Published RCTs have found that oral NMN raises blood NAD+ levels, and several trials in healthy middle-aged adults, older men, and women with prediabetes have reported improvements in markers such as muscle oxygen utilization, aerobic capacity in runners, and insulin sensitivity. A multicenter double-blind placebo-controlled trial found dose-dependent changes in NAD+ levels but limited functional outcomes. No trial has demonstrated effects on human aging, longevity, or disease incidence. Long-term safety data beyond 12 weeks is sparse. NMN's regulatory status in the US has been clarified: the FDA reversed a prior drug-exclusion determination in September 2025 and confirmed NMN is lawful as a dietary supplement, though New Dietary Ingredient notification requirements apply.

Safety and risks

Short-term trials at doses up to 1,200 mg/day reported no serious adverse events, but trial durations have generally been 8-12 weeks and participant numbers are small. A theoretical concern exists based on preclinical data that elevating NAD+ could support proliferation in pre-existing cancer cells; this has not been evaluated in human trials and the clinical relevance is unknown. NMN is a supplement, not a drug; manufacturing quality varies significantly across commercial products, and label accuracy is not guaranteed without third-party testing. Interactions with chemotherapy agents that target NAD+ metabolism (e.g., NAMPT inhibitors) are theoretically possible; not studied. Effects in populations with diabetes, cardiovascular disease, or active malignancy have not been adequately characterized. Metabolic variability in conversion from NMN to NAD+ is documented; some individuals may not achieve meaningful NAD+ elevation at standard doses.

Interactions

Potentially additive with other NAD+ precursors (NR, niacin); combination effects are not clinically studied. Theoretical interaction with PARP inhibitors and NAMPT inhibitors used in oncology.

Compounding legality

NMN is not a compounded drug; it is legally sold as a dietary supplement in the US as of September 2025 (FDA reversed its prior drug-exclusion position). New Dietary Ingredient notification is required from manufacturers. It is not an FDA-approved drug for any indication.

Sources

NMN is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).